Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLPTNASDAQ:LUNGNYSE:MLSSNASDAQ:SMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$13.64-3.3%$12.84$5.11▼$19.22$381.65M1.03227,591 shs343,499 shsLUNGPulmonx$3.68+9.2%$5.83$3.36▼$9.41$148.15M0.65309,180 shs434,078 shsMLSSMilestone Scientific$0.93-2.6%$0.96$0.58▼$1.39$72.52M0.93131,157 shs179,217 shsSMTISanara MedTech$34.37+6.2%$31.05$25.86▼$39.08$305.48M1.3825,900 shs73,885 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro-3.81%-1.73%+18.92%-23.15%+132.76%LUNGPulmonx+8.55%+2.79%-29.90%-46.12%-56.24%MLSSMilestone Scientific-2.61%-7.48%+2.80%-21.59%+38.05%SMTISanara MedTech+6.08%+6.21%+18.31%-0.41%+9.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLPTClearPoint Neuro2.4646 of 5 stars3.53.00.00.04.00.00.6LUNGPulmonx3.8895 of 5 stars4.44.00.00.03.42.50.6MLSSMilestone Scientific1.4403 of 5 stars3.50.00.00.01.31.70.0SMTISanara MedTech1.8071 of 5 stars3.51.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro 3.00Buy$25.0083.28% UpsideLUNGPulmonx 2.78Moderate Buy$12.07228.03% UpsideMLSSMilestone Scientific 3.00Buy$1.2535.11% UpsideSMTISanara MedTech 3.00Buy$48.5041.11% UpsideCurrent Analyst Ratings BreakdownLatest MLSS, CLPT, SMTI, and LUNG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $25.003/26/2025SMTISanara MedTechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$46.00 ➝ $46.003/26/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $51.003/10/2025LUNGPulmonxJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy3/10/2025LUNGPulmonxMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Equal Weight3/10/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy3/10/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$17.00 ➝ $17.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$31.39M12.16N/AN/A$0.86 per share15.86LUNGPulmonx$87.47M1.69N/AN/A$3.09 per share1.19MLSSMilestone Scientific$8.63M8.40N/AN/A$0.11 per share8.41SMTISanara MedTech$86.67M3.52N/AN/A$5.22 per share6.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$22.09M-$0.70N/AN/AN/A-59.64%-62.10%-38.39%5/13/2025 (Estimated)LUNGPulmonx-$60.84M-$1.44N/AN/AN/A-67.31%-55.36%-33.53%7/29/2025 (Estimated)MLSSMilestone Scientific-$6.93M-$0.07N/A∞N/A-52.01%-60.26%-40.23%N/ASMTISanara MedTech-$4.30M-$1.14N/AN/AN/A-10.71%-19.86%-10.91%5/14/2025 (Estimated)Latest MLSS, CLPT, SMTI, and LUNG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SMTISanara MedTech-$0.31N/AN/AN/A$23.48 millionN/A5/13/2025Q1 2025CLPTClearPoint Neuro-$0.15N/AN/AN/A$8.21 millionN/A5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million3/25/2025Q4 2024SMTISanara MedTech-$0.19-$0.18+$0.01-$0.18$22.75 million$26.31 million2/26/2025Q4 2024CLPTClearPoint Neuro-$0.15-$0.20-$0.05-$0.20$8.23 million$7.77 million2/19/2025Q4 2024LUNGPulmonx-$0.45-$0.33+$0.12-$0.33$22.29 million$23.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint NeuroN/A4.543.61LUNGPulmonx0.407.706.77MLSSMilestone ScientificN/A2.851.86SMTISanara MedTech0.762.232.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%LUNGPulmonx91.04%MLSSMilestone Scientific5.79%SMTISanara MedTech8.10%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro6.97%LUNGPulmonx6.80%MLSSMilestone Scientific24.75%SMTISanara MedTech54.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro11027.98 million25.90 millionOptionableLUNGPulmonx25040.26 million37.24 millionOptionableMLSSMilestone Scientific3078.38 million58.61 millionOptionableSMTISanara MedTech608.89 million4.01 millionNot OptionableMLSS, CLPT, SMTI, and LUNG HeadlinesRecent News About These CompaniesSanara MedTech (SMTI) to Release Earnings on WednesdayMay 12 at 1:30 AM | americanbankingnews.comSanara MedTech (SMTI) Projected to Post Earnings on WednesdayMay 9, 2025 | marketbeat.comWith 31% ownership, Sanara MedTech Inc. (NASDAQ:SMTI) insiders have a lot riding on the company's futureMay 7, 2025 | uk.finance.yahoo.comSanara MedTech Inc. (NASDAQ:SMTI) Shares Acquired by JPMorgan Chase & Co.May 4, 2025 | marketbeat.comMarshall Wace LLP Takes Position in Sanara MedTech Inc. (NASDAQ:SMTI)May 3, 2025 | marketbeat.comRenaissance Technologies LLC Grows Position in Sanara MedTech Inc. (NASDAQ:SMTI)May 2, 2025 | marketbeat.comSanara MedTech (NASDAQ:SMTI) Stock Price Down 2.6% - Here's What HappenedApril 24, 2025 | marketbeat.comSanara MedTech Inc. to Report Q1 2025 Financial Results on May 14, 2025April 23, 2025 | quiverquant.comSanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025April 23, 2025 | globenewswire.comSanara MedTech to Present at Investor ShowcaseApril 22, 2025 | tipranks.comSanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025April 10, 2025 | globenewswire.comSanara MedTech (SMTI) Stock Jumps 8.1%: Will It Continue to Soar?April 10, 2025 | zacks.comWhere Sanara MedTech Stands With AnalystsMarch 28, 2025 | benzinga.comEarnings call transcript: Sanara Medtech Q4 2024 shows strong growthMarch 27, 2025 | uk.investing.comAnalysts Are Bullish on Top Healthcare Stocks: X4 Pharmaceuticals (XFOR), Sanara MedTech (SMTI)March 27, 2025 | markets.businessinsider.comSanara MedTech Shares Fall on Wider 4Q LossMarch 25, 2025 | marketwatch.comSanara MedTech targets pilot launch of Tissue Health Plus in Q2 2025March 25, 2025 | msn.comWhy Sanara MedTech Inc.’s (SMTI) Stock Is Down 12.58%March 25, 2025 | aaii.comSanara MedTech Inc. (SMTI) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | seekingalpha.comSanara MedTech Inc. Reports 49% Q4 Revenue Growth and 33% Annual Revenue Increase for 2024March 25, 2025 | quiverquant.comSanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)March 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLSS, CLPT, SMTI, and LUNG Company DescriptionsClearPoint Neuro NASDAQ:CLPT$13.64 -0.47 (-3.33%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$14.42 +0.79 (+5.76%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Pulmonx NASDAQ:LUNG$3.68 +0.31 (+9.20%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$3.85 +0.17 (+4.62%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Milestone Scientific NYSE:MLSS$0.93 -0.02 (-2.61%) Closing price 05/12/2025 03:59 PM EasternExtended Trading$0.91 -0.02 (-1.75%) As of 05/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.Sanara MedTech NASDAQ:SMTI$34.37 +2.02 (+6.24%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$34.27 -0.10 (-0.29%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
